Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the potential of two medications from Carmot currently in development, CT-388 in obese adults without type 2 diabetes and CT-868 in obese adults with type 2 diabetes

Ticker(s): RHHBY, Carmot Therapeutics

Who's the expert?

Institution: University of Arkansas Medical Services Health

Director of the diabetes program at UAMS Health
Clinical interests include type 1 diabetes, type 2 diabetes, Diabetes management with exercise, insulin pumps, closed-look insulin pump systems, and continuous glucose monitoring systems
Manages about 600 patients with type 2 diabetes and is familiar with Brenzavvy via the published clinical trials

Interview Goal

This call will focus on the data from from Carmot's Phase 1 data on CT-388, a novel GLP-1/GIP Receptor Modulator for improved Insulin Sensitivity in Overweight/Obese Adults and the Phase 2 data on CT-868, a novel Dual GLP-1/GIP Receptor Modulator, in Overweight/Obese T2D Adults.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.